IRTC vs. TNDM, HAE, NVRO, PEN, BLCO, TMDX, PRCT, NARI, CNMD, and NVCR
Should you be buying iRhythm Technologies stock or one of its competitors? The main competitors of iRhythm Technologies include Tandem Diabetes Care (TNDM), Haemonetics (HAE), Nevro (NVRO), Penumbra (PEN), Bausch + Lomb (BLCO), TransMedics Group (TMDX), PROCEPT BioRobotics (PRCT), Inari Medical (NARI), CONMED (CNMD), and NovoCure (NVCR). These companies are all part of the "medical" sector.
Tandem Diabetes Care (NASDAQ:TNDM) and iRhythm Technologies (NASDAQ:IRTC) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, community ranking, dividends and media sentiment.
iRhythm Technologies has lower revenue, but higher earnings than Tandem Diabetes Care. iRhythm Technologies is trading at a lower price-to-earnings ratio than Tandem Diabetes Care, indicating that it is currently the more affordable of the two stocks.
Tandem Diabetes Care has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, iRhythm Technologies has a beta of 1.24, indicating that its stock price is 24% more volatile than the S&P 500.
Tandem Diabetes Care presently has a consensus price target of $51.25, suggesting a potential upside of 27.97%. iRhythm Technologies has a consensus price target of $130.88, suggesting a potential upside of 48.15%. Given Tandem Diabetes Care's stronger consensus rating and higher possible upside, analysts plainly believe iRhythm Technologies is more favorable than Tandem Diabetes Care.
Tandem Diabetes Care has a net margin of -18.37% compared to Tandem Diabetes Care's net margin of -25.33%. iRhythm Technologies' return on equity of -34.38% beat Tandem Diabetes Care's return on equity.
In the previous week, Tandem Diabetes Care had 1 more articles in the media than iRhythm Technologies. MarketBeat recorded 10 mentions for Tandem Diabetes Care and 9 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.47 beat Tandem Diabetes Care's score of 0.82 indicating that Tandem Diabetes Care is being referred to more favorably in the media.
Tandem Diabetes Care received 181 more outperform votes than iRhythm Technologies when rated by MarketBeat users. However, 66.22% of users gave iRhythm Technologies an outperform vote while only 61.22% of users gave Tandem Diabetes Care an outperform vote.
Summary
Tandem Diabetes Care beats iRhythm Technologies on 11 of the 16 factors compared between the two stocks.
Get iRhythm Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRTC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IRTC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
iRhythm Technologies Competitors List
Related Companies and Tools
